Literature DB >> 18491437

What role will 'gliptins' play in glycemic control?

Zachary Bloomgarden1, Andrew Drexler.   

Abstract

The gliptins, a new class of oral drugs for type 2 diabietes mellitus, lower blood glucose levels by a novel mechanism: ie, by inhibiting the enzyme dipeptidyl peptidase 4, thereby increasing the circulating levelsof incretins (gut hormones that can boost insulin levels). This article reviews the current evidence on the effectiveness of gliptins and suggests several ways in which these agents could be used in diabetes treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18491437     DOI: 10.3949/ccjm.75.4.305

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  2 in total

Review 1.  Update on the treatment of type 2 diabetes mellitus.

Authors:  Juan José Marín-Peñalver; Iciar Martín-Timón; Cristina Sevillano-Collantes; Francisco Javier Del Cañizo-Gómez
Journal:  World J Diabetes       Date:  2016-09-15

2.  Gliptins: a new class of oral antidiabetic agents.

Authors:  K G Seshadri; M H B Kirubha
Journal:  Indian J Pharm Sci       Date:  2009-11       Impact factor: 0.975

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.